| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC2741 |
| Trial ID | NCT04989803 |
| Disease | B-Cell Lymphoma |
| Altered gene | CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KITE-363/KITE-753 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Study of KITE-363 in Participants With Relapsed and/or Refractory B-cell Lymphoma |
| Year | 2021 |
| Country | United States |
| Company sponsor | Kite, A Gilead Company |
| Other ID(s) | KT-US-499-0150|2020-000562-41 |
| Cohort 1 | |||||||||||
|
|||||||||||